Crunching the numbers for ROIV... Refresh in a moment for the full analysis.
Roivant Sciences Ltd. (ROIV)
Healthcare
weak
$28.33
Updated: 2026-04-12
43
TradeApes Score
reduce
Financial Strength
40
Weak
Operating Trend
40
Weak
Valuation
40
Weak
Capital Allocation
30
Weak
Risk
80
Strong
Key Findings
+
Strong liquidity — current assets more than 2× current liabilities
−
Excessive stock comp — SBC above 15% of revenue, wealth transfer to employees
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Create Free Account
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.